{"title":"专家观点:2019年美国血液学会年会重点介绍骨髓瘤细胞治疗","authors":"Chutima Kunacheewa, Elisabet E. Manasanch","doi":"10.1002/acg2.93","DOIUrl":null,"url":null,"abstract":"<p>Autologous stem cell transplantation has been part of standard of treatment in multiple myeloma for 2 decades. The data showed improving progression-free survival and overall survival. Despite the improvement of new drugs, myeloma patients continue to relapse New cell therapy, chimeric antigen receptor T-cell therapy have been explored in heavily pretreated patients. In this commentary, we highlight studies presented at the American Society of Hematology (ASH) Annual Meeting held in Orlando, FL in December 2019.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.93","citationCount":"0","resultStr":"{\"title\":\"Expert perspective: Highlights on myeloma cell therapy from the American Society of Hematology Annual Meeting 2019\",\"authors\":\"Chutima Kunacheewa, Elisabet E. Manasanch\",\"doi\":\"10.1002/acg2.93\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Autologous stem cell transplantation has been part of standard of treatment in multiple myeloma for 2 decades. The data showed improving progression-free survival and overall survival. Despite the improvement of new drugs, myeloma patients continue to relapse New cell therapy, chimeric antigen receptor T-cell therapy have been explored in heavily pretreated patients. In this commentary, we highlight studies presented at the American Society of Hematology (ASH) Annual Meeting held in Orlando, FL in December 2019.</p>\",\"PeriodicalId\":72084,\"journal\":{\"name\":\"Advances in cell and gene therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-05-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/acg2.93\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in cell and gene therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acg2.93\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cell and gene therapy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acg2.93","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Expert perspective: Highlights on myeloma cell therapy from the American Society of Hematology Annual Meeting 2019
Autologous stem cell transplantation has been part of standard of treatment in multiple myeloma for 2 decades. The data showed improving progression-free survival and overall survival. Despite the improvement of new drugs, myeloma patients continue to relapse New cell therapy, chimeric antigen receptor T-cell therapy have been explored in heavily pretreated patients. In this commentary, we highlight studies presented at the American Society of Hematology (ASH) Annual Meeting held in Orlando, FL in December 2019.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
